Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous abatacept in Japanese children and adolescents with active juvenile idiopathic arthritis
2016-000940-32Phase 3
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2016
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of abatacept in juvenile idiopathic arthritis (JIA), sponsored by Bristol Myers Squibb. Primary endpoint: ACR Pediatric 30 response rate.
02
Drugs
abatacept
03
Conditions
juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on 2016-000940-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000940-32.